IP Library › Granted Patent US 12,404,262
Granted Patent B2
US 12,404,262 · App. 18/061,150 · Granted Sep 2, 2025

Therapeutic compounds for HIV virus infection

Inventors: Gediminas J. Brizgys (San Carlos, CA); Chienhung Chou (Dublin, CA); Hang Chu (San Mateo, CA); Julie Farand (San Mateo, CA); Michael Graupe (Pacifica, CA); Tezcan Guney (Foster City, CA); Darryl Kato (San Francisco, CA); Jiayao Li (Foster City, CA); John O. Link (San Francisco, CA); James B. C. Mack (San Mateo, CA); Dong Min Mun (Newark, CA); Scott D. Schroeder (Union City, CA); William J. Watkins (Saratoga, CA); Qiaoyin Wu (Foster City, CA); Jennifer R. Zhang (Union City, CA)
Assignee: Gilead Sciences, Inc.
C07D401/14A61K45/06C07F9/65583
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,262
App. No.
18/061,150
Granted
Sep 2, 2025
Kind
B2
Abstract

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Claims (127)

1. A compound of Formula I,

or a pharmaceutically acceptable salt thereof,

wherein

X is —C(O)C(O)NR 1 R 1 , —C(O)C(O)OR 2 , —(C 1-6 alkyl)OR 3 , —C(O)NR 4 R 5 , —C(O)OR 6 , or —C(O)C 1-10 alkyl,

wherein the C 1-10 alkyl is optionally substituted with one 4-7 membered monocyclic heterocyclyl,

wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , and R c ;

each R 1 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , and R c ;

R 2 is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , and R c ;

R 3 is —P(O)(OH) 2 , —C(O)R 3a , —C(O)OR 3a , —C(O)NR 3b R 3b , —C(O)C(O)OR 3a , —S(O) 2 R 3a , —S(O) 2 NR 3b R 3b , or —S(O) 2 OR 3a ;

R 3a is H or C 1-6 alkyl, wherein the C 1-6 alkyl is substituted with 1-3 groups independently selected from —CN, R a , R d , —OC(O)R 9 , —OC(O)C(O)OR 9 , —NR 10 C(O)R 9 , —NR 10 C(O)NR 10 R 10 , —NR 10 C(O)OR 9 , —NR 10 C(O)C(O)OR 9 , —NR 10 C(═NR 10a )NR 10 R 10 , and —NR 10 S(O) 2 R 9 ;

each R 3b independently is R d or C 1-6 alkyl, wherein the C 1-6 alkyl is substituted with 1-3 groups independently selected from —CN, R a , R d , —OC(O)R 9 , —OC(O)C(O)OR 9 , —NR 10 C(O)R 9 , —NR 10 C(O)NR 10 R 10 , —NR 10 C(O)OR 9 , —NR 10 C(O)C(O)OR 9 , —NR 10 C(═NR 10a )NR 10 R 10 , and —NR 10 S(O) 2 R 9 ;

R 4 is H, or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —B(OH) 2 , —CN, halogen, R a , R b , and R c ;

R 5 is H, C 1-6 alkyl, or 8-10 membered fused bicyclic heteroaryl,

wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —B(OH) 2 , —CN, halogen, R a , R b , R c , and R 5a ,

wherein the 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , Rb, R c and R 5b ;

each R 5a independently is 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, or 8-10 membered fused bicyclic heteroaryl,

wherein the 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, and 8-10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , and R c ;

each R 5b independently is C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , and R c ;

R 6 is C 1-10 alkyl or C 3-7 monocyclic cycloalkyl,

wherein the C 1-10 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , R c , and —OC(O)(C 2-6 alkenylene)C(O)OR 9 , 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, and 8-10 membered fused bicyclic heteroaryl,

wherein the C 3-7 monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , and R c ;

each R a independently is —P(O)(OH) 2 or —OP(O)(OH) 2 ;

each R b independently is —C(O)R 7 , —C(O)OR 7 , —C(O)NR 8 R 8 , —C(O)C(O)OR 7 , —C(═NR 8a )(NR 8 R 8 ), —S(O) 2 R 7 , —S(O) 2 NR 8 R 8 , or —S(O) 2 OR 7 ;

each R c independently is —OR 7 , —OC(O)R 7 , —OC(O)C(O)OR 7 , —(O(C 1-4 alkyl)) n OR 7a , —NR 8 R 8 , —N + R 8 R 8 R 8a , —NR 8 C(O)R 7 , —NR 8 C(O)NR 8 R 8 , —NR 8 C(O)OR 7 , —NR 8 C(O)C(O)OR 7 , —NR 8 C(═NR 8a )NR 8 R 8 , or —NR 8 S(O) 2 R 7 ;

each R 7 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R d , and R e ;

each R 7a independently is H, —P(O)(OH) 2 , or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R d , and R e ;

each R 8 independently is H, R d , or C 1-6 alkyl,

wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R d , and R e ;

each R 8a independently is H or C 1-3 alkyl;

each R d independently is —C(O)R 9 , —C(O)OR 9 , —C(O)NR 10 R 10 , —C(O)C(O)OR 9 , —C(═NR 10a )(NR 10 R 10 ), —S(O) 2 R 9 , —S(O) 2 NR 10 R 10 , or —S(O) 2 OR 9 ;

each R e independently is —OR 9 , —OC(O)R 9 , —OC(O)C(O)OR 9 , —NR 10 R 10 , —N + R 10 R 10 R 10a , —NR 10 C(O)R 9 , —NR 10 C(O)NR 10 R 10 , —NR 10 C(O)OR 9 , —NR 10 C(O)C(O)OR 9 , —NR 10 C(═NR 10a )NR 10 R 10 , or —NR 10 S(O) 2 R 9 ;

each R 9 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from CN, halogen, R a , R f , and R g ;

each R 10 independently is H, R f or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R f , and R g ;

each R 10a independently is H or C 1-3 alkyl;

each R f independently is —C(O)R 11 , —C(O)OR 11 , —C(O)NR 11 R 11 , —C(O)C(O)OR 11 , —C(═NR 11a )(NR 11 R 11 ), —S(O) 2 R 11 , —S(O) 2 NR 11 R 11 , or —S(O) 2 OR 11 ;

each R g independently is —OR 11 , —OC(O)R 11 , —OC(O)C(O)OR 11 , —NR 11 R 11 , —N + R 11 R 11 R 11a , —NR 11 C(O)R 11 , —NR 11 C(O)NR 11 R 11 , —NR 11 C(O)OR 11 , —NR 11 C(O)C(O)OR 11 , —NR 11 C(═NR 11a )NR 11 R 11 , or —NR 11 S(O) 2 R 11 ;

each R 11 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, CN, halogen, —COOH, and R a ;

each R 11a independently is H or C 1-3 alkyl;

n is 1, 2, 3, 4, or 5;

wherein each 4 membered monocyclic heterocyclyl has 1 ring heteroatom selected from N, O, and S;

wherein each 5-7 membered monocyclic heterocyclyl has 1-2 ring heteroatoms independently selected from N, O, and S; and

wherein each 5-6 membered monocyclic heteroaryl and 8-10 membered fused bicyclic heteroaryl independently have 1-4 ring heteroatoms independently selected from N, O, and S.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

X is —C(O)C(O)NR 1 R 1 , —C(O)C(O)OR 2 , —(C 1-6 alkyl)OR 3 , —C(O)NR 4 R 5 , —C(O)OR 6 , or —C(O)C 1-10 alkyl,

wherein the C 1-10 alkyl is optionally substituted with one 4-7 membered monocyclic heterocyclyl,

wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , and R c ;

each R 1 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, and R a ;

R 2 is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, and R a ;

R 3 is —C(O)R 3a , —C(O)C(O)OR 3a , or —P(O)(OH) 2 ;

R 3a is H or C 1-6 alkyl, wherein the C 1-6 alkyl is substituted with 1-3 groups independently selected from —CN, R a , R d , —OC(O)R 9 , —OC(O)C(O)OR 9 , —NR 10 C(O)R 9 , —NR 10 C(O)NR 10 R 10 , —NR 10 C(O)OR 9 , —NR 10 C(O)C(O)OR 9 , —NR 10 C(═NR 10a )NR 10 R 10 , and —NR 10 S(O) 2 R 9 ;

R 4 is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —B(OH) 2 , —CN, halogen, R a , R b , and R c ;

R 5 is H, or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , R c , and R 5a ;

each R 5a independently is 4-7 membered monocyclic heterocyclyl or phenyl,

wherein the 4-7 membered monocyclic heterocyclyl and phenyl are each independently optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , and R c ;

R 6 is C 1-10 alkyl or C 3-7 monocyclic cycloalkyl,

wherein the C 1-10 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R b , R c , and —OC(O)(C 2-6 alkenylene)C(O)OR 9 , 4-7 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl,

wherein the C 3-7 monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, —NR 8 R 8 , and R a ;

each R a independently is —P(O)(OH) 2 or —OP(O)(OH) 2 ;

each R b independently is —C(O)R 7 , —C(O)OR 7 , —C(O)NR 8 R 8 , —C(O)C(O)OR 7 , —C(═NR 8a )(NR 8 R 8 ), —S(O) 2 R 7 , —S(O) 2 NR 8 R 8 , or —S(O) 2 OR 7 ;

each R c independently is —OR 7 , —OC(O)R 7 , —OC(O)C(O)OR 7 , —(O(C 1-4 alkyl)) n OR 7a , —NR 8 R 8 , —N + R 8 R 8 R 8a , —NR 8 C(O)R 7 , —NR 8 C(O)NR 1 R 1 , —NR 8 C(O)OR 7 , —NR 8 C(O)C(O)OR 8 , —NR 8 C(═NR 8a )NR 8 R 8 , or —NR 8 S(O) 2 R 7 ;

each R 7 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R d , and R e ;

each R 7a independently is H or —P(O)(OH) 2 ;

each R 8 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, R a , R d , and R e ;

each R 8a independently is H or C 1-3 alkyl;

each R d independently is —C(O)R 9 , —C(O)OR 9 , —C(O)NR 10 R 10 , —C(O)C(O)OR 9 , —C(═NR 10a )(NR 10 R 10 ), —S(O) 2 R 9 , —S(O) 2 NR 10 R 10 , or —S(O) 2 OR 9 ;

each R e independently is —OR 9 , —OC(O)R 9 , —OC(O)C(O)OR 9 , —NR 10 R 10 , —N + R 10 R 10 R 10a , —NR 10 C(O)R 9 , —NR 10 C(O)NR 10 R 10 , —NR 10 C(O)OR 9 , —NR 10 C(O)C(O)OR 9 , —NR 10 C(═NR 10a )NR 10 R 10 , or —NR 10 S(O) 2 R 9 ;

each R 9 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, CN, halogen, —C(O)OH, and R a ;

each R 10 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, and R a ;

each R 10a independently is H or C 1-3 alkyl;

n is 1, 2, 3, 4, or 5;

wherein each 4 membered monocyclic heterocyclyl has 1 ring heteroatom selected from N, O, and S;

wherein each 5-7 membered monocyclic heterocyclyl has 1-2 ring heteroatoms independently selected from N, O, and S; and

wherein each 5-6 membered monocyclic heteroaryl and 8-10 membered fused bicyclic heteroaryl independently have 1-4 ring heteroatoms independently selected from N, O, and S.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof,

wherein

X is —C(O)C(O)NR 1 R 1 , —C(O)C(O)OR 2 , —(C 1-6 alkyl)OR 3 , —C(O)NR 4 R 5 , —C(O)OR 6 , or —C(O)C 1-10 alkyl,

wherein the C 1-10 alkyl is optionally substituted with one 4-7 membered monocyclic heterocyclyl,

wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, —C(═NR 8 a)(NR 1 R 1 ), and R a ;

each R 1 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, and R a ;

R 2 is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, and R a ;

R 3 is —C(O)R 3a , —C(O)C(O)OR 3a , or —P(O)(OH) 2 ;

R 3a is H or C 1-6 alkyl, wherein the C 1-6 alkyl is substituted with 1-3 groups independently selected from —CN, —C(O)OR 9 , and R a ;

R 4 is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, and R a ;

R 5 is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OR 7 , —OC(O)C(O)OR 7 , —NR 8 R 8 , —N + R 8 R 8 R 8a , —NR 8 C(O)OR 7 , —NR 8 C(O)C(O)OR 8 , —NR 8 C(═NR 8a )NR 8 R 8 , R a , and R 5a ;

each R 5a independently is 4-7 membered monocyclic heterocyclyl or phenyl, wherein the 4-7 membered monocyclic heterocyclyl and phenyl are each independently optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, —C(═NR 8a )(NR 8 R 8 ), and R a ;

R 6 is C 1-10 alkyl or C 3-5 monocyclic cycloalkyl,

wherein the C 1-10 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OR 7 , —S(O) 2 OR 7 , —(O(C 1-4 alkyl)) n OR 7a , —NR 8 R 8 , R a , —OC(O)(C 2-6 alkenylene)C(O)OR 9 , 4-7 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl,

wherein the C 3-5 monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, —NR 8 R 8 , and R a ;

each R a independently is —P(O)(OH) 2 or —OP(O)(OH) 2 ;

each R 7 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OR 9 , —NR 10 R 10 , and R a ;

each R 7a independently is H or —P(O)(OH) 2 ;

each R 8 independently is H, —C(O)OR 9 , —C(O)C(O)OR 9 , —C(═NR 10a )(NR 10 R 10 ), or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OR 9 , and R a ;

each R 8a independently is H or C 1-3 alkyl;

each R 9 independently is H or C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted with 1-3 groups independently selected from —OH, CN, halogen, —C(O)OH, and R a ;

each R 10 independently is H or C 1-4 alkyl, wherein the C 1-4 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OH, and R a ;

each R 10a independently is H or C 1-3 alkyl;

n is 1, 2, 3, 4, or 5;

wherein each 4 membered monocyclic heterocyclyl has 1 ring heteroatom selected from N, O, and S;

wherein each 5-7 membered monocyclic heterocyclyl has 1-2 ring heteroatoms independently selected from N, O, and S; and

wherein each 5-6 membered monocyclic heteroaryl and 8-10 membered fused bicyclic heteroaryl independently have 1-4 ring heteroatoms independently selected from N, O, and S.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O)C(O)NR 1 R 1 , and each R 1 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —C(O)OH and R a .

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O)C(O)OR 2 , and R 2 is H or C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted with 1-3 groups independently selected from —C(O)OH and R a .

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —(C 1-4 alkyl)OR 3 , and R 3 is —P(O)(OH) 2 , —C(O)R 3a or —C(O)C(O)OR 3a .

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O)NR 4 R 5 ;

R 4 is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —B(OH) 2 , —C(O)OR 7 , —C(O)NR 8 R 8 , —S(O) 2 R 7 , —S(O) 2 NR 8 R 8 , —S(O) 2 OR 7 , —NR 8 C(O)R 7 , —NR 8 C(O)NR 8 R 8 , —NR 8 S(O) 2 R 7 , and R a ; and

R 5 is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —B(OH) 2 , —C(O)OR 7 , —C(O)NR 8 R 8 , —OC(O)C(O)OR 7 , —NR 8 R 8 , —N + R 8 R 8 R 8a , —NR 8 C(O)OR 7 , —NR 8 C(O)C(O)OR 8 , —NR 8 C(═NR 8a )NR 8 R 8 , —S(O) 2 R 7 , —S(O) 2 NR 8 R 8 , —S(O) 2 OR 7 , —NR 8 C(O)R 7 , —NR 8 C(O)NR 8 R 8 , —NR'S(O) 2 R 7 , R a , and R 5a .

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O)OR 6 , and R 6 is C 1-10 alkyl, wherein the C 1-10 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —CN, halogen, —C(O)OR 7 , —S(O) 2 OR 7 , —(O(C 1-4 alkyl)) n OR 7a , —NR 8 R 8 , R a , —OC(O)(C 2-6 alkenylene)C(O)OR 9 , 5-6 membered monocyclic heterocyclyl, and 6 membered monocyclic heteroaryl.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O)OR 6 and R 6 is C 1-5 alkyl, wherein the C 1-5 alkyl is substituted with one —(O(C 1-4 alkyl)) n OR 7a and wherein n is 1, 2, or 3.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O)OR 6 and R 6 is C 1-4 alkyl, wherein the C 1-4 alkyl is substituted with pyridinyl or morpholinyl.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O)OR 6 and R 6 is C 3-5 monocyclic cycloalkyl, wherein the C 3-5 monocyclic cycloalkyl is substituted with 1-2 groups independently selected from —C(O)OH, —NR 1 R 1 , and R a .

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —C(O) C 1-10 alkyl, wherein the C 1-10 alkyl is optionally substituted with one 4-7 membered monocyclic heterocyclyl, wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —OH, —C(O)OH, —C(═NR 8a )(NR 8 R 8 ), and R a .

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 7 independently is H or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, —NR 10 R 10 , and R a .

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 8 independently is H, —C(O) OR 9 , —C(O)C(O)OH, —C(═NH)NH 2 , or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, C(O)OH, and R a .

15. The compound of claim 1 , which is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1 , which is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , which is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , which is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , which is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , which is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

22. The pharmaceutical composition of claim 21 , further comprising one, two, three, or four additional therapeutic agents.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2023
From: BRIZGYS, GEDIMINAS J.; CHOU, CHIENHUNG; CHU, HANG; FARAND, JULIE; GRAUPE, MICHAEL; GUNEY, TEZCAN; KATO, DARRYL; LI, JIAYAO; LINK, JOHN O.; MACK, JAMES B.C.; MUN, DONG MIN; SCHROEDER, SCOTT D.; WATKINS, WILLIAM J.; WU, QIAOYIN; ZHANG, JENNIFER R.
To: GILEAD SCIENCES, INC.
Reel/Frame 062433/0890 →
Continuity (2)
Provisional Application 63285745 · Dec 3, 2021
Related Publication 20230212148A1 · Jul 6, 2023
References Cited (299)
US 3845770A · Theeuwes et al. · 1974 [cited by applicant]
US 4326525A · Swanson et al. · 1982 [cited by applicant]
US 4816570A · Farquhar · 1989 [cited by applicant]
US 4902514A · Barclay et al. · 1990 [cited by applicant]
US 4968788A · Farquhar · 1990 [cited by applicant]
US 4992445A · Lawter et al. · 1991 [cited by applicant]
US 5001139A · Lawter et al. · 1991 [cited by applicant]
US 5023252A · Hseih · 1991 [cited by applicant]
US 5616345A · Geoghegan et al. · 1997 [cited by applicant]
US 5663159A · Starrett, Jr. et al. · 1997 [cited by applicant]
US 5792756A · Starrett, Jr. et al. · 1998 [cited by applicant]
US 5922695A · Arimilli et al. · 1999 [cited by applicant]
US 5935946A · Munger, Jr. et al. · 1999 [cited by applicant]
US 5977089A · Arimilli et al. · 1999 [cited by applicant]
US 7390791B2 · Becker et al. · 2008 [cited by applicant]
US 7803788B2 · Becker et al. · 2010 [cited by applicant]
US 8193225B2 · Schneider et al. · 2012 [cited by applicant]
US 8263627B2 · Barrow et al. · 2012 [cited by applicant]
US 8435968B2 · Greig et al. · 2013 [cited by applicant]
US 8748412B2 · Liao et al. · 2014 [cited by applicant]
US 8754065B2 · Liu et al. · 2014 [cited by applicant]
US 8835488B2 · Yamashita et al. · 2014 [cited by applicant]
US 9012441B2 · Bondy et al. · 2015 [cited by applicant]
US 9050344B2 · Brizgys et al. · 2015 [cited by applicant]
US 9216996B2 · Jin et al. · 2015 [cited by applicant]
US 9220710B2 · Bondy et al. · 2015 [cited by applicant]
US 9540343B2 · Bondy et al. · 2017 [cited by applicant]
US 9670205B2 · Aktoudianakis et al. · 2017 [cited by applicant]
US 9730936B2 · Baszcynski et al. · 2017 [cited by applicant]
US 9789089B2 · Bondy et al. · 2017 [cited by applicant]
US 9873680B2 · Brizgys et al. · 2018 [cited by applicant]
US 9944619B2 · Bondy et al. · 2018 [cited by applicant]
US 9951043B2 · Brizgys et al. · 2018 [cited by applicant]
US 10071885B2 · O'Brien et al. · 2018 [cited by applicant]
US 10071985B2 · Graupe et al. · 2018 [cited by applicant]
US 10294234B2 · Bacon et al. · 2019 [cited by applicant]
US 10370342B2 · Chin et al. · 2019 [cited by applicant]
US 10370358B2 · Bondy et al. · 2019 [cited by applicant]
US 10640499B2 · Chin et al. · 2020 [cited by applicant]
US 10654827B2 · Graupe et al. · 2020 [cited by applicant]
US 10696657B2 · Vandehey · 2020 [cited by applicant]
US 10836746B2 · Brizgys et al. · 2020 [cited by applicant]
US 10849892B2 · Houston et al. · 2020 [cited by applicant]
US 11034668B2 · Bondy et al. · 2021 [cited by applicant]
US 11078208B1 · Bacon et al. · 2021 [cited by applicant]
US 11084832B2 · Chu et al. · 2021 [cited by applicant]
US 11117886B2 · Vandebey et al. · 2021 [cited by applicant]
US 11266638B2 · Houston et al. · 2022 [cited by applicant]
US 11267799B2 · Shi · 2022 [cited by applicant]
US 11267801B2 · Brizgy et al. · 2022 [cited by applicant]
US 11680064B2 · Chou et al. · 2023 [cited by applicant]
US 11753399B2 · Brizgy et al. · 2023 [cited by applicant]
US 11757825B2 · Farand et al. · 2023 [cited by applicant]
US 11807625B2 · Bekerman et al. · 2023 [cited by applicant]
US 20050282805A1 · Hangeland et al. · 2005 [cited by applicant]
US 20070083045A1 · Di Francesco et al. · 2007 [cited by applicant]
US 20080234251A1 · Doherty et al. · 2008 [cited by applicant]
US 20080306050A1 · Doherty et al. · 2008 [cited by applicant]
US 20100029585A1 · Dietsch et al. · 2010 [cited by applicant]
US 20100129306A1 · Julien et al. · 2010 [cited by applicant]
US 20100143301A1 · Desai et al. · 2010 [cited by applicant]
US 20100189796A1 · Stokbroekx · 2010 [cited by applicant]
US 20100249176A1 · Barrow et al. · 2010 [cited by applicant]
US 20110092485A1 · Burgess et al. · 2011 [cited by applicant]
US 20110118235A1 · Burgess et al. · 2011 [cited by applicant]
US 20120045761A1 · Jagannath et al. · 2012 [cited by applicant]
US 20120082658A1 · Hershberg · 2012 [cited by applicant]
US 20120219615A1 · Coukos et al. · 2012 [cited by applicant]
US 20130165489A1 · Cocklin et al. · 2013 [cited by applicant]
US 20130251673A1 · Flores et al. · 2013 [cited by applicant]
US 20140045849A1 · McGowan et al. · 2014 [cited by applicant]
US 20140066432A1 · Burgess et al. · 2014 [cited by applicant]
US 20140073642A1 · Embrechts et al. · 2014 [cited by applicant]
US 20140088085A1 · Burgess et al. · 2014 [cited by applicant]
US 20140142085A1 · Bondy et al. · 2014 [cited by applicant]
US 20140221346A1 · Halcomb et al. · 2014 [cited by applicant]
US 20140221347A1 · Brizgys et al. · 2014 [cited by applicant]
US 20140221356A1 · Jin et al. · 2014 [cited by applicant]
US 20140221378A1 · Miyazaki et al. · 2014 [cited by applicant]
US 20140221380A1 · Miyazaki et al. · 2014 [cited by applicant]
US 20140221417A1 · Halcomb et al. · 2014 [cited by applicant]
US 20140221421A1 · Bondy et al. · 2014 [cited by applicant]
US 20140275167A1 · Hartman · 2014 [cited by applicant]
US 20140296266A1 · Hu et al. · 2014 [cited by applicant]
US 20140303164A1 · Brizgys et al. · 2014 [cited by applicant]
US 20140350031A1 · McGowan et al. · 2014 [cited by applicant]
US 20150104511A1 · Malhotra et al. · 2015 [cited by applicant]
US 20160067224A1 · Bondy et al. · 2016 [cited by applicant]
US 20160083368A1 · Brizgys et al. · 2016 [cited by applicant]
US 20160108030A1 · Brizgys et al. · 2016 [cited by applicant]
US 20160250215A1 · Baszcynski et al. · 2016 [cited by applicant]
US 20160289229A1 · Aktoudianakis et al. · 2016 [cited by applicant]
US 20160368881A1 · Bondy et al. · 2016 [cited by applicant]
US 20170137405A1 · Bondy et al. · 2017 [cited by applicant]
US 20180051005A1 · Graupe · 2018 [cited by examiner]
US 20180194746A1 · Bondy et al. · 2018 [cited by applicant]
US 20180258097A1 · Bacon et al. · 2018 [cited by applicant]
US 20180273508A1 · Brizgys et al. · 2018 [cited by applicant]
US 20180370950A1 · Graupe et al. · 2018 [cited by applicant]
US 20190014787A1 · Greenshields et al. · 2019 [cited by applicant]
US 20190083478A1 · Houston et al. · 2019 [cited by applicant]
US 20190084963A1 · Shi · 2019 [cited by applicant]
US 20190125747A1 · Rezaei et al. · 2019 [cited by applicant]
US 20190300505A1 · Allan et al. · 2019 [cited by applicant]
US 20190345136A1 · Brizgys et al. · 2019 [cited by applicant]
US 20190375726A1 · Bondy et al. · 2019 [cited by applicant]
US 20200038389A1 · Bauer · 2020 [cited by applicant]
US 20200262815A1 · Graupe et al. · 2020 [cited by applicant]
US 20200369647A1 · Allan et al. · 2020 [cited by applicant]
US 20200397772A1 · Houston et al. · 2020 [cited by applicant]
US 20210009555A1 · Brizgys et al. · 2021 [cited by applicant]
US 20210188815A1 · Bekerman et al. · 2021 [cited by applicant]
US 20220009904A1 · Allan et al. · 2022 [cited by applicant]
US 20220249460A1 · Houston et al. · 2022 [cited by applicant]
US 20220251069A1 · Shi · 2022 [cited by applicant]
US 20220267302A1 · Brizgys et al. · 2022 [cited by applicant]
US 20230012449A1 · Bondy et al. · 2023 [cited by applicant]
US 20230038823A1 · Chou et al. · 2023 [cited by applicant]
US 20230203069A1 · Nair et al. · 2023 [cited by applicant]
US 20230312567A1 · Chou et al. · 2023 [cited by applicant]
US 20240376077A1 · Graupe et al. · 2024 [cited by applicant]
CN 101910133 · 2010 [cited by applicant]
CN 107207498 · 2017 [cited by applicant]
JP 2013515007 · 2013 [cited by applicant]
JP 2013533306 · 2013 [cited by applicant]
WO WO1991019721 · 1991 [cited by applicant]
WO WO2003002530 · 2003 [cited by applicant]
WO WO2003002553 · 2003 [cited by applicant]
WO WO2004050643 · 2004 [cited by applicant]
WO WO2004071448 · 2004 [cited by applicant]
WO WO2004096286 · 2004 [cited by applicant]
WO WO2005087725 · 2005 [cited by applicant]
WO WO2005123680 · 2005 [cited by applicant]
WO WO2006015261 · 2006 [cited by applicant]
WO WO2006110157 · 2006 [cited by applicant]
WO WO2007070826 · 2007 [cited by applicant]
WO WO2008013622 · 2008 [cited by applicant]
WO WO2008118849 · 2008 [cited by applicant]
WO WO2009005677 · 2009 [cited by applicant]
WO WO2009010804 · 2009 [cited by applicant]
WO WO2009062285 · 2009 [cited by applicant]
WO WO2009114677 · 2009 [cited by applicant]
WO WO2010130034 · 2010 [cited by applicant]
WO WO2011059887 · 2011 [cited by applicant]
WO WO2011084733 · 2011 [cited by applicant]
WO WO2011143772 · 2011 [cited by applicant]
WO WO2011144666A1 · 2011 [cited by applicant]
WO WO2012003497 · 2012 [cited by applicant]
WO WO2012003498 · 2012 [cited by applicant]
WO WO2012020301 · 2012 [cited by applicant]
WO WO2012065062 · 2012 [cited by applicant]
WO WO2012145728 · 2012 [cited by applicant]
WO WO2013006738 · 2013 [cited by applicant]
WO WO2013006792 · 2013 [cited by applicant]
WO WO2013091096 · 2013 [cited by applicant]
WO WO2013159064 · 2013 [cited by applicant]
WO WO2014016358 · 2014 [cited by applicant]
WO WO2014023813 · 2014 [cited by applicant]
WO WO2014028931 · 2014 [cited by applicant]
WO WO2014056953 · 2014 [cited by applicant]
WO WO2014076221 · 2014 [cited by applicant]
WO WO2014100323 · 2014 [cited by applicant]
WO WO2014110297 · 2014 [cited by applicant]
WO WO2014110298 · 2014 [cited by applicant]
WO WO2014110323 · 2014 [cited by applicant]
WO WO2014128189 · 2014 [cited by applicant]
WO WO2014128213 · 2014 [cited by applicant]
WO WO2014134566 · 2014 [cited by applicant]
WO WO2015008097 · 2015 [cited by applicant]
WO WO2015061518 · 2015 [cited by applicant]
WO WO2015130966 · 2015 [cited by applicant]
WO WO2016033243 · 2016 [cited by applicant]
WO WO2016040084 · 2016 [cited by applicant]
WO WO2016172424 · 2016 [cited by applicant]
WO WO2016172425 · 2016 [cited by applicant]
WO WO2017007689 · 2017 [cited by applicant]
WO WO2018035359 · 2018 [cited by applicant]
WO WO2018145021 · 2018 [cited by applicant]
WO WO2018203235 · 2018 [cited by applicant]
WO WO2019035904 · 2019 [cited by applicant]
WO WO2019035973 · 2019 [cited by applicant]
WO WO2020018459 · 2020 [cited by applicant]
WO WO2024220624A1 · 2024 [cited by applicant]
Patani, G. A et al. “Bioisosterism: A Rational Approach in Drug Design.” Chemical reviews 1996, vol. 96, 8: 3147-3176. (Year: 1996). [cited by examiner]
[No Author Listed], “2-[9-(Difluoromethyl)-5,5-difluoro-7,8-diazatricylo[4.4.0.02,4]nona-1(6),8-dien-7-yl]acetic acid,” PubChem CID 71186949, Mar. 21, 2013, 18 pages. [cited by applicant]
[No Author Listed], “3-Methyl-3-methylsulfonylbut-l-yne,” PubChem CID 14241469, Feb. 9, 2002, 16 pages. [cited by applicant]
[No Author Listed], CAS registry No. 1620056-83-8, Aug. 6, 2014, 1 page. [cited by applicant]
Bastin et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities,” Organic Process Research & Development, Jul. 2000, 4(5): 427-435. [cited by applicant]
Benzaria et al., “Synthesis, In Vitro Antiviral Evaluation, and Stability Studies of Bis(S-Acyl-2-Thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy)Ethyl]adenine (PMEA) as Potential PMEA Prodrugs with Improved Oral… [cited by applicant]
Berge et al., “Pharmaceutical Salts,” J. Pharma. Sci., 1977, 66(1): 1-19. [cited by applicant]
Blair et al., “HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention,” PLoS Pathog., 2010, 6(12): e1001220, 10 pages. [cited by applicant]
Briggs et al., “Structural Organization of Authentic, Mature HIV-1 Virions and Cores,” The EMBO Journal, 2003, 22(7): 1707-1715. [cited by applicant]
Brown et al., “Highly Enantioselective Cu-Catalyzed Conjugate Additions of Dialkylzinc Reagents to Unsaturated Furanones and Pyranones: Preparation of Air-Stable and Catalytically Active Cu-Peptide,” Angew. Chem. Int. E… [cited by applicant]
Bundgaard, “Design and Application of Prodrugs,” Chapter 5 in A Textbook of Drug Design and Development, Krogsgaard-Larsen, P. et al. eds., Harwood Academic Publishers, Chur, Switzerland, 1991, pp. 113-191. [cited by applicant]
Campbell et al., “HIV-1 Capsid: The Multifaceted Key Player in HIV-1 Infection,” Nat Rev Microbial., 2015, 13(8): 471-483. [cited by applicant]
Carnes et al., “Inhibitors of the HIV-1 Capsid, A Target of Opportunity,” Curr. Opin. HIV AIDS, 2018, 13(4):359-365. [cited by applicant]
Chin et al., “Direct Visualization of HIV-1 Replication Intermediates Shows That Capsid and CPSF6 Modulate HIV-1 Intra-Nuclear Invasion and Integration”, Cell Repotis, 2015, 13:1717-1731. [cited by applicant]
Choy et al., “Synthesis of irreversible HIV-1 protease inhibitors containing sulfonamide and sulfone as amide bond isosteres,” Bioorganic & Medicinal Chemistry Letters, Oct. 1997, 7(20):2635-38. [cited by applicant]
Cos et al., “Structure-Activity Relationship and Classification of Flavonoids as Inhibitors of Xanthine Oxidase and Su peroxide Scavengers,” J. Natl. Prod., 1998, 61:71-76. [cited by applicant]
Cossy et al., “Ring Opening of Cyclopropylketones Induced by Photochemical Electron Transfer,” Tetrahedron, Oct. 1995, 51 (43):11751-11764. [cited by applicant]
Curreli et al., “Virtual Screening Based Identification of Novel Small-molecule Inhibitors Targeted to the HIV-1 Capsid,” Bioorganic & Medicinal Chemistry, 2011, 19:77-90. [cited by applicant]
De Lombaert et al., “N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, A New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors,” J. Med. Chem., Feb. 1994, 37(4):498-511. [cited by applicant]
Fader et al., “Optimization of a 1,5 dihydrobenzo[b][1,4]diazepine-2,4-dione Series of HIV Capsid Assembly Inhibitors 2: Structure-Activity Relationships (SAR) of the C3-Phenyl Moiety,” Bioorganic & Medicinal Chemistry … [cited by applicant]
Farquhar et al., “Biologically Reversible Phosphate-Protective Groups,” J. Pharm. Sci., Mar. 1983, 72(3):324-325. [cited by applicant]
Fields, “Methods for Removing the Fmoc Group,” Methods in Molecular Biology, 1994, 35:17-27. [cited by applicant]
Fontes Ferreira da Cunha et al., “4D-QSAR Models of HOE/BAY-793 Analogues as HIV-1 Protease Inhibitors,” QSAR & Combinatorial Science, 2005, 24(2): 240-253. [cited by applicant]
Forshey et al., “Formation of a Human Immunodeficiency Virus Type 1 Core of Optimal Stability Is Crucial for Viral Replication,” J. Virology, 2002, 76(11) p. 5667-5677. [cited by applicant]
Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci., 1984, 5(12):524-527. [cited by applicant]
Ganser et al., “Assembly and Analysis of Conical Models for the HIV-1 Core,” Science, 1999, 283: 80-82. [cited by applicant]
Ganser-Pornillos et al., “Structure of Full-Length HIV-1 CA: A Model for the Mature Capsid Lattice,” Cell, 2007, 131(1):70-9, 29 pages. [cited by applicant]
Hagmann, “The many roles for fluorine in medicinal chemistry,” J. Med. Chem., 2008, 51(15):4359-4369. [cited by applicant]
Hammer et al., “Antiretroviral Treatment of Adult HIV Infection. 2008 Recommendations of the International AIDS Society: USA Panel,” JAMA, Aug. 2008, 300(5):555-570. [cited by applicant]
Hanack et al., “cis—und trans bicyclo [3.1.0] hexano-(2),” Chemische Berichte, 1964, 97(6):1669-1672, XP055573746 (with English translation). [cited by applicant]
Hodgson et al. “Intramolecular Cyclopropanation of Unsaturated Terminal Epoxides,” J. Am. Chem. Soc., 2004, 126(28):8664-8665. [cited by applicant]
Hodgson et al., “Intramolecular Cyclopropanation of Unsaturated Terminal Epoxides and Chlorohydrins,” J. Am. Chem. Soc., 2007, 129(14):4456-4462. [cited by applicant]
Hung et al., “Large-Scale Functional Purification of Recombinant HIV-1 Capsid,” PLOS One, 2013, 8(3):e58035, 11 pages. [cited by applicant]
Ishiyama et al., “Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters,” J. Org. Chem., 1995, 60(23):7508-7510. [cited by applicant]
Jarvis et al., “Conquering HIV's capsid”, C&EN Chicago, Jul. 2017, 95(31): 23-25. [cited by applicant]
Jeong, “Synthesis of Tetrasubstituted Pyrazones and Pyrazone N-Oxides,” Tetrahedron Letters, 2010, 51 (6):974-976. [cited by applicant]
Jin et al., “SAR and Molecular Mechanism Study of Novel Acylhydrazone Compounds Targeting HIV-1 CA,” Bioorganic & Medicinal Chemistry, 2010, 18: 2135-2140. [cited by applicant]
Jouvenet et al., “Plasma Membrane Is the Site of Productive HIV-1 Particle Assembly,” PLoS Biol., 2006, 4(12):e435, 15 pages. [cited by applicant]
Kashima et al., “New Peptide Synthesis Using the Ozonolysate of 2-(1-Phthalimido)alkyl-5-Phenyloxazoles,” J. Heterocyclic Chem., 1991, 28: 1241-1244. [cited by applicant]
Kelly et al., “Structure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA Protein,” Journal of Molecular Biology, 2007, 373(2):355-66. [cited by applicant]
Khamnei et al., “Neighboring Group Catalysis in the Design of Nucleotide Prodrugs,” J. Med. Chem., 1996, 39(20):4109-4115. [cited by applicant]
Kim et al., “Discovery of a New HIV-1 Inhibitor Scaffold and Synthesis of Potential Prodrugs of Indazoles,” Bioorganic & Medicinal Chemistry Letters, 2013, 23(10):2888-2892. [cited by applicant]
Kocienski, “Carbonyl Protecting Groups,” Chapter 5 in Protecting Groups, Thieme Publishing Group: New York, NY, May 1994, pp. 155-184. [cited by applicant]
Kocienski, “Carboxyl Protecting Groups,” Chapter 4 in Protecting Groups, Thieme Publishing Group: New York, NY, May 1994, pp. 118-154. [cited by applicant]
Kocienski, “Diol Protecting Groups,” Chapter 3 in Protecting Groups, Thieme Publishing Group: New York, NY, May 1994, pp. 95-117. [cited by applicant]
Kocienski, “Hydroxyl Protecting Groups,” Chapter 2 in Protecting Groups, Thieme Publishing Group: New York, NY, May 1994, pp. 21-94. [cited by applicant]
Kocienski, “Protecting Groups: An Overview,” Chapter 1 in Protecting Groups, Thieme Publishing Group: New York, NY, May 1994, pp. 1-20. [cited by applicant]
Lad et al., “Functional Label-Free Assays for Characterizing the in Vitro Mechanism of Action of Small Molecule Modulators of Capsid Assembly” Biochemistry, 2015, 54: 2240-2248. [cited by applicant]
Lamorte et al., “Discovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid Complexes” Antimicrobial Agents and Chemotherapy, 2015, 57(10): 4622-4631. [cited by applicant]
Lazerwith et al., “New Antiretrovirals for HIV and Antivirals for HBV,” in Comprehensive Medicinal Chemistry, 3rd Edition, 2017, pp. 1-36. [cited by applicant]
Lee et al., “Flexible Use of Nuclear Import Pathways by HIV-1,” Cell Host & Microbe, 2010, 7:221-233. [cited by applicant]
Lemke et al., “Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site Within the N-Terminal Domain of the Viral CA Protein,” J. Virol., Jun. 2012, 86(12):6643-6655. [cited by applicant]
Macmillan et al., “Evaluation of alternative solvent in common amide coupling reactions: replacement of dicloromethane and N,N-dimethiformamide,” Green Chem, 2013, 15: 596-600. [cited by applicant]
Matreyek et al., “Nucleoporin NUP153 Phenylalanine-Glycine Motifs Engage a Common Binding Pocket within the HIV-1 Capsid Protein to Mediate Lentiviral Infectivity” PLOS Pathogens, 2013, 9(10): e1003693. 21 pages. [cited by applicant]
Mitchell et al., “Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-Acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate,” J. Chem. Soc. Perkin Trans. … [cited by applicant]
Miyaura et al., “Palladium-Catalyzed Cross-Coupling Reactions of Oganoboron Compounds,” Chem Rev, 1995, 95:2457-2483. [cited by applicant]
Molina et al., “On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection”, The New England Journal of Medicine, Dec. 2015, 353:2237-2246. [cited by applicant]
Montalbetti et al., “Amide bond formation and peptide coupling,” Tetrahedon, 2005, 61:10827-10852. [cited by applicant]
Morissette et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids,” Advanced Drug Delivery Reviews, Feb. 2004, 56(3):275-300. [cited by applicant]
Nicolaou et al., “Palladium-Catalyzed Cross-Coupling Reactions in Total Synthesis,” Angew Chem Int Ed, 2005, 44:4442-4489. [cited by applicant]
Ovais et al. “Synthesis, antiproliferative and anti-inflammatory activities of some novel 6-aryl-2-(p-(methanesulfonyl)phenyl)-4,5-dihydropyridazi-3(2H)-ones,” European Journal of Medicinal Chemistry, 2013, 67:352-358. [cited by applicant]
Owen et al., “Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy,” Advances Drug Delivery Reviews, 2016, 103:144-156. [cited by applicant]
Palella et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection,” N Engl. J Med., 1998, 338:853-860. [cited by applicant]
Patel et al., “Poloxamers: a pharmaceutical excipients with therapeutic behaviors,” International Journal of Pharm Tech Research, 2009, 1(2):299-303. [cited by applicant]
Pornillos et al., “Atomic level modeling of the HIV capsid,” Nature, Jan. 2011, 469(7330):424-427. [cited by applicant]
Pornillos et al., “X-ray Structures of the Hexameric Building Block of the HIV Capsid” Cell, 2009, 137(7): 1282-1292. [cited by applicant]
Powers et al., “Synthesis of Methyl-, Fluoro-, and Chloro-substituted 6-Hydroxyisoindolin-1-1-Ones,” Tetrahedron Letters, 2009, 50(12):1267-1269. [cited by applicant]
Price et al., “CPSF6 Defines a Conserved Capsid Interface That Modulates HIV-1 Replication,” PLOS Pathogens, 2012, 8(8):e1002896, 14 pages. [cited by applicant]
Puech et al., “Intracellular Delivery of Nucleoside Monophosphates Through a Reductase-Mediated Activation Process,” Antiviral Res., Oct. 1993, 22(2-3):155-174. [cited by applicant]
Pungpo et al., “Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives,” SAR and QSAR in Environmental Research, 2006, 17(4):353-370. [cited by applicant]
Registry (STN) [online], Mar. 22, 2010 [date of retrieval: Nov. 12, 2018], CAS registry No. 1213065-84-9. [cited by applicant]
Registry (STN) [online], Mar. 23, 2010 [date of retrieval: Nov. 12, 2018], CAS registry No. 1213495-28-3. [cited by applicant]
Registry (STN)[online], Nov. 15, 1991, STN Registry No. 137349-29-2, 1 page. [cited by applicant]
Rihn et al., “Extreme Genetic Fragility of the HIV-1 Capsid,” PLOS One, 2013, 9(6):e1003461, 25 pages. [cited by applicant]
Shi et al., “Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Capsid Destabilization,” Journal of Virology, 2011, 85(1): 542-549. [cited by applicant]
Siddiqui et al., “The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure-Activity Relationship,” J. Med. Chem., 1999, 42:393… [cited by applicant]
Silverman, “The Organic Chemistry of Drug Design and Drug Action,” Elsevier, 2004, pp. 121-169. [cited by applicant]
Silvestri et al., “Novel Indolyl Aryl Sulfones Active against HIV-1 Carrying NNRTI Resistance Mutations: Synthesis and SAR Studies,” Journal of Medical Chemistry, 2003, 46(12): 2482-2493. [cited by applicant]
Smith et al., “Evolutionary Dynamics of Complex Networks of HIV Drug-Resistant Strains: The Case of San Francisco,” Science, 2010, 327(5966):697-701. [cited by applicant]
Sticht et al., “A peptide inhibitor of HIV-1 assembly in vitro,” Nature Structural & Molecular Biology, 2005, 12(8): 671-677. [cited by applicant]
Sublocade Product Label, issued: Nov. 2017, 43 pages. [cited by applicant]
Taiwo, “Understanding Transmitted HIV Resistance Through the Experience in the USA,” International Journal of Infectious Diseases, 2009, 13(5):552-559. [cited by applicant]
Talele, “The ‘Cyclopropyl Fragment’ is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules,” Journal of Medicinal Chemistry, 2016, 59(19):8712-8756. [cited by applicant]
Tanaka et al., “One-Pot Synthesis of Metalated Pyridines from Two Acetylenes, a Nitrile, and a Titanium(II) Alkoxide,” J. Am. Chem. Soc., 2005, 127(21):7774-7780. [cited by applicant]
Tang et al., “Antiviral Inhibition of the HIV-1 Capsid Protein,” J. Mol. Biol., 2003, 327: 1013-1020. [cited by applicant]
Thenin-Houssier et al., “HIV-1 capsid inhibitors as antiretroviral agents,” Curr. HIV Res., 2016, 14(3):270-282. [cited by applicant]
Tse et al., “Discovery of Novel Potent HIV Capsid Inhibitors with Long-Acting Potential,” Abstract for Oral Presentation at the Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2017, 18 pages. [cited by applicant]
Tsiang et al., “A Trimer of Dimers Is the Basic Building Block for Human Immunodeficiency Virus-1 Capsid Assembly,” Biochemistry, 2012, 51: 4416-4428. [cited by applicant]
Wu et al., “Selective Inhibitors of Tumor Progression Loci-2(Tpl2) Kinase with Potent Inhibition of TNF-Alpha Production in Human Whole Blood,” Bioorg. Med. Chem. Lett., 2009, 19(13):3485-3488. [cited by applicant]
Xianghui et al., “In Silico Virtual Screening,” Biotechnology in the Post-Genome Era, 2003, 16 pages. [cited by applicant]
Yadav et al., “Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients,” Indian J. Pharm. Sci., 2009, 71(4):359-370. [cited by applicant]
Yale, “The trifluoromethyl group in medicinal chemistry,” J. Med. Chem., 1958, 1(2):121-133. [cited by applicant]
Zhou et al. “HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry,” Journal of Virology, 2015, 89(17): 9068-9079. [cited by applicant]
Jindal et al., “Nevirapine loaded Poloxamer 407/Pluronic P123 mixed micelles: Optimization of formulation and in vitro evaluation,” Colloids and Surfaces B: Biointerfaces, May 2015, 129:100-106. [cited by applicant]
Klooster et al., “Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation,” Antimicrobial Agents and Chemotherapy, May 2010, 54(5):2042-2050. [cited by applicant]
Landovitz et al., “The promise and pitfalls of long acting injectable agents for HIV prevention,” Current Opinion in HIV and AIDS, Jan. 2016, (1):122-128. [cited by applicant]
Magiorakos et al., “Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance,” Clinical Microbiology and I… [cited by applicant]
Palombo et al., “Prodrug and conjugate drug delivery strategies for improving HIV/ADS therapy,” Journal of drug delivery science and technology, Jan. 2009, 19(1): 31 pages. [cited by applicant]
Seremeta et al., “Poly(ϵ-caprolactone), Eudragit® RS 100 and poly(ϵ-caprolactone)/Eudragit® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz,” Colloids and Surfaces B: Biointerf… [cited by applicant]
Spreen et al., “Long-acting injectable antiretrovirals for HIV treatment and prevention,” Current Opinion in HIV and AIDS, Nov. 8, 2013, 8(6):565-571. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020080813, dated Mar. 9, 2023, 13 pages. [cited by applicant]
Bhattacharya et al., Structural Basis of HIV-1 Capsid Recognition by PF74 and CPSF6, PNAS, 2014, 111(52):18625-18630. [cited by applicant]
Brittain, “Polymorphism in pharmaceutical solids,” Marcel Dekker, Inc., 1999, 235-238. [cited by applicant]
Jornada et al., “The Prodrug Approach: A Successful Tool for Improving Drug Solubility,” Molecules, Dec. 29, 2015, 21(1):42, 31 pages. [cited by applicant]
Yang et al., “Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors,” Bioorganic & Medicinal Chemistry, May 2016, 24(9):2125-2136. [cited by applicant]
Yant et al., “PF74 Inhibits Multiple HIV Capsid Functions Independently of Host Cyclophilin A and CPSF6,” Abstract for Poster Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Mass… [cited by applicant]
Office Action in Taiwanese Appln. No. 111146361, mailed on Nov. 28, 2023, 8 pages (with English translation). [cited by applicant]
[No. Author], “Sunlenca; Annex I: Summary of Product Characteristics,” Jun. 27, 2023, retrieved on Feb. 8, 2024, retrieved from URL<https://www.ema.europa.eu/en/documents/product-information/sunlenca-epar-product-inform… [cited by applicant]
ClinicalTrials.gov [online], “Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People with HIV,” NCT05052996, last updated on Jan. 19, 2024, retrieved on… [cited by applicant]
Wong et al., “SPR Assay Development to Characterize Caps id Inhibitors Binding & MOA,” Poster Presented at the Developments in Protein Interaction (DiPIA), La Jolla, CA, 2014, 8 pages. [cited by applicant]
Yant et al., “An Improved PF74 Analog Inhibits Multiple HIV Capsid Functions Independently of Host Cyclophilin A and CPSF6,” Poster Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), Boston… [cited by applicant]
Zheng et al. “GS-6207: A Novel, Potent and Selective First-In-Class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential,” Poster Presented at ID Week 2018, San Franc… [cited by applicant]
Office Action in Taiwanese Appln. No. 111146361, mailed on Mar. 27, 2024, 5 pages (with English translation). [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2020080813, dated Jun. 13, 2024, 8 pages. [cited by applicant]
Office Action for Japanese Appln. No. 2024-532836, mailed Apr. 22, 2025, 7 pages (with English translation). [cited by applicant]
Lopes et al., “Acyloxymethyl as a drug protecting group. Part 6: N-acyloxymethyl- and N-[(aminocarbonyloxy) methyl] sulfonamides as prodrugs of agents containing a secondary sulfonamide group,” Bioorganic & medicinal ch… [cited by applicant]
Cited By (2)
US 12,594,267 US 12,636,279